Cutaneous B-Cell Lymphoproliferative Disorders

Swerdlow, Steven H.; Quintanilla-Martı́nez, Leticia; Willemze, Rein; Kinney, Marsha C.

doi:10.1309/ajcpnlc9nc9wtqyy

Cited by 53 publications

(20 citation statements)

References 80 publications

(109 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…[66] PCFCLs do not show the BCL-2 protein and its locus containing t (14;18) translocation, which is distinctive of systemic follicular lymphomas and a fraction of systemic DLBCL LT.[60676869]…”

Section: Primary Cutaneous Follicle Center Lymphomamentioning

confidence: 99%

A literature revision in primary cutaneous B-cell lymphoma

et al. 2017

View full text Add to dashboard Cite

The term “Primary Cutaneous B-Cell Lymphoma” (PCBCL) comprehends a variety of lymphoproliferative disorders characterized by a clonal proliferation of B-cells primarily involving the skin. The absence of evident extra-cutaneous disease must be confirmed after six-month follow-up in order to exclude a nodal non-Hodgkin's lymphoma (NHL) with secondary cutaneous involvement, which may have a completely different clinical behavior and prognosis. In this article, we have summarized the clinico-pathological features of main types of PCBCL and we outline the guidelines for management based on a review of the available literature.

show abstract

Section: Primary Cutaneous Follicle Center Lymphomamentioning

confidence: 99%

A literature revision in primary cutaneous B-cell lymphoma

et al. 2017

View full text Add to dashboard Cite

show abstract

“…Generally, the cutaneous T-cell lymphomas are more common than cutaneous B-cell lymphomas, which are a quarter of all primary cutaneous lymphomas (5, 6, 7). Notably, the PCDLBCL, also named ‘leg type’, is an infrequent lymphoma with a poor prognosis (5, 6, 7). …”

Section: Discussionmentioning

confidence: 99%

“…Classically, the identification of a primary cutaneous lymphoma necessitates that there is no extracutaneous disease involved at the moment of the diagnosis (4). Although the cutaneous T-cell lymphomas (CTCLs) are the more common subtype, the cutaneous B-cell lymphomas (CBCLs) range from 25% to 30% of all primary cutaneous lymphomas (5, 6, 7). To note, the primary cutaneous diffuse large B-cell lymphoma (PCDLBCL), leg type, is a rare and aggressive lymphoma, which represents approximately 4% of all cutaneous lymphomas and 20% of all primary CBCLs (5, 6, 7).…”

Section: Introductionmentioning

confidence: 99%

“…Although the cutaneous T-cell lymphomas (CTCLs) are the more common subtype, the cutaneous B-cell lymphomas (CBCLs) range from 25% to 30% of all primary cutaneous lymphomas (5, 6, 7). To note, the primary cutaneous diffuse large B-cell lymphoma (PCDLBCL), leg type, is a rare and aggressive lymphoma, which represents approximately 4% of all cutaneous lymphomas and 20% of all primary CBCLs (5, 6, 7). PCDLBCL often affects elderly individuals and females seem to be more affected than male (5, 6, 7).…”

Section: Introductionmentioning

confidence: 99%

“…To note, the primary cutaneous diffuse large B-cell lymphoma (PCDLBCL), leg type, is a rare and aggressive lymphoma, which represents approximately 4% of all cutaneous lymphomas and 20% of all primary CBCLs (5, 6, 7). PCDLBCL often affects elderly individuals and females seem to be more affected than male (5, 6, 7). Traditionally, the cutaneous manifestation of this lymphoma is a red or violaceous tumors that becomes apparent on a leg (4).…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Primary cutaneous B-cell lymphoma and chronic leg ulcers in a patient with type 2 diabetes

Mantovani¹,

Perrone²,

Stoico³

et al. 2017

Endocrinology, Diabetes &Amp; Metabolism Case Reports

View full text Add to dashboard Cite

The incidences of type 2 diabetes mellitus and many cancers are rapidly increasing worldwide. Diabetes is a strong risk factor for some cancers (including lymphomas) and is also associated with adverse cancer outcomes. After gastrointestinal tract, the skin is the second most frequent extranodal site involved by non-Hodgkin lymphomas and the cutaneous B-cell lymphomas (CBCLs) range from 25% to 30% of all primary cutaneous lymphomas. The primary cutaneous diffuse large B-cell lymphoma (PCDLBCL) is an aggressive lymphoma with a poor prognosis, representing roughly 20% of all primary CBCLs. Classically, the cutaneous manifestation of this lymphoma is a red or violaceous tumors arising on a leg. To date, despite the large body of evidence suggesting that diabetes is strongly associated with an increased risk of some cancers, very little information is available regarding a possible association between type 2 diabetes and primary cutaneous diffuse large B-cell lymphoma. In this report, we will present the case of a white adult patient with type 2 diabetes with chronic leg ulcers complicated by a primary cutaneous diffuse large B-cell lymphoma.Learning points:Diabetes mellitus is increasing worldwide as well as the incidence of many cancers.Diabetes mellitus is a powerful risk factor for some cancers (including lymphomas) and is strongly associated with adverse cancer outcomes.Seen that diabetes is strongly associated with an increased risk of cancers (including cutaneous lymphomas), clinicians should always keep in mind this complication in elderly patients with type 2 diabetes, even in a chronic leg ulcer with hypertrophy of the wound edge, which is hard to heal and does not have the typical characteristics of a diabetic or vascular ulcer. In these cases, a biopsy should be performed to rule out a neoplasm.Early diagnosis and correct management of cancer in a patient with type 2 diabetes are crucial to improve clinical outcomes.

show abstract

Cutaneous B‐cell lymphomas: 2021 update on diagnosis, risk‐stratification, and management

2020

View full text Add to dashboard Cite

Disease Overview Approximately one‐fourth of primary cutaneous lymphomas are B‐cell derived and are generally classified into three distinct subgroups: primary cutaneous follicle center lymphoma (PCFCL), primary cutaneous marginal zone lymphoma (PCMZL), and primary cutaneous diffuse large B‐cell lymphoma, leg type (PCDLBCL, LT). Diagnosis Diagnosis and disease classification is based on histopathologic review and immunohistochemical staining of an appropriate skin biopsy. Pathologic review and an appropriate staging evaluation are necessary to distinguish primary cutaneous B‐cell lymphomas from systemic B‐cell lymphomas with secondary skin involvement. Risk‐Stratification Disease histopathology remains the most important prognostic determinant in primary cutaneous B‐cell lymphomas. Both PCFCL and PCMZL are indolent lymphomas that infrequently disseminate to extracutaneous sites and are associated with 5‐year survival rates that exceed 95%. In contrast, PCDLBCL, LT is an aggressive lymphoma with an inferior prognosis. Risk‐Adapted Therapy Both PCFCL and PCMZL patients with solitary or relatively few skin lesions may be effectively managed with local radiation therapy. While single‐agent rituximab may be employed for patients with more widespread skin involvement, multi‐agent chemotherapy is rarely appropriate. In contrast, management of patients with PCDLBCL, LT is comparable to the management of patients with systemic DLBCL.

show abstract

Cutaneous B-Cell Lymphoproliferative Disorders

Cited by 53 publications

References 80 publications

A literature revision in primary cutaneous B-cell lymphoma

A literature revision in primary cutaneous B-cell lymphoma

Primary cutaneous B-cell lymphoma and chronic leg ulcers in a patient with type 2 diabetes

Cutaneous B‐cell lymphomas: 2021 update on diagnosis, risk‐stratification, and management

Contact Info

Product

Resources

About